Daptomycin for outpatient parenteral antibiotic therapy: a European registry experience

Seaton, R.A., Gonzalez-Ramallo, V.J., Prisco, V., Marcano-Lozada, M., Gonzalez-Ruiz, A., Gallegos, B., Menichetti, F., Loeffler, J., Bouylout, K. and Chaves, R.L. (2013) Daptomycin for outpatient parenteral antibiotic therapy: a European registry experience. International Journal of Antimicrobial Agents, 41(5), pp. 468-472. (doi: 10.1016/j.ijantimicag.2013.01.019)

Abstract

A retrospective analysis of data from patients receiving daptomycin as outpatient parenteral antimicrobial therapy (OPAT) within the European Cubicin Outcomes Registry and Experience (EU-CORESM) was performed. Of 4592 enrolled patients in 15 countries, 550 (12%) received daptomycin OPAT. Of these, 149 (27%) received daptomycin without hospital admission, 84% had significant underlying diseases and 44% were ≥65 years of age. Most frequently treated infections were complicated skin and soft-tissue infections (28%), osteomyelitis (17%), foreign body/prosthetic infections (15%) and endocarditis (14%). In patients with culture results available, Staphylococcus aureus and coagulase-negative staphylococci were the most commonly isolated primary pathogens [n = 218 (46%) and n = 102 (21%), respectively]. Daptomycin was typically used at doses of 6 mg/kg (n = 210; 38%) and 4 mg/kg (n = 160; 29%), with concomitant antibiotics used in 41%. The median treatment duration was 22 days (range 1–300 days), with a median of 13 OPAT days (range 1–290 days). Overall clinical success was observed in 89%, with high success rates across the wide range of infections, including those caused by meticillin-resistant and meticillin-susceptible S. aureus (88% and 90%, respectively). Daptomycin exhibited a favourable safety profile; 3.1% of patients discontinued treatment owing to an adverse event. These data demonstrate that daptomycin is effective and well tolerated in the treatment of a wide range of Gram-positive infections in the outpatient setting. Ease of administration of daptomycin, via a daily 2-min injection, and its efficacy and safety combine to make it an attractive treatment option for OPAT.

• Item Type: Articles
• Status: Published
• Refereed: Yes
• Glasgow Author(s) Enlighten ID: Seaton, Dr Andrew
• Authors: Seaton, R.A., Gonzalez-Ramallo, V.J., Prisco, V., Marcano-Lozada, M., Gonzalez-Ruiz, A., Gallegos, B., Menichetti, F., Loeffler, J., Bouylout, K., and Chaves, R.L.
• College/School: College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing
• Journal Name: International Journal of Antimicrobial Agents
• ISSN: 0924-8579